Didymin Exhibits Different Cytotoxicity Patterns on U-87 MG Human Glioblastoma Cells and Orchestrates the Release of Substance P (SP) and Interleukin-6 (IL-6) in a Time Depending Manner
Objectives: This study aims to investigate the cytotoxic effects of didymin on the U-87 MG Human Glioblastoma cell line, besides, its effects on levels of Substance P and Interleukin 6 (IL-6) released from the cells.
Methods: The cytotoxic effects of didymin on glioblastoma were determined at the end of 24, 48, and 72 hours incubation periods. The effects on the levels of Substance P and Interleukin 6 (IL-6) determined via Elisa.
Results: Didymin in the range of 100 – 1,56 μM/ml doses did not show cytotoxic effects at the end of the 24th and 48th hour. At the end of the 72-hours a cytotoxic effect was observed at a dose of 100 μM/ml. SP increased at 100 µM/ml and 50 µM/ml doses at the end of the 24 and 48 hours incubation periods and decreased significantly at the end of the 72nd hour. IL-6 increased significantly at 100 μM/ml at the end of the 24th hour. It caused a significant increase in each dose at the 48th hour, while a significant increase was observed only at the 50 μM/ml dose at the 72nd hour.
Conclusion: The cytotoxic effect of didymin was observed in single dose. Didymin increased the level of inflammation marker IL-6, in a time and dose-dependent manner and decreased the level of SP at the end of the 72nd hour. This was the first study, which exhibits the effects of didymin on SP and IL-6 released from U-87.
1. McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016;34:981−98.
2. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008- 2012. Neuro Oncol 2015;17(Suppl 4):iv1-iv62.
3. Altmann KH, Gertsch J. Anticancer drugs from nature- natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007;24:327−57.
4. Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2002;2:143−8.
5. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann Oncol 2017;28:1457−72.
6. Yao Q, Lin MT, Zhu Y Di, Xu HL, Zhao YZ. Recent trends in potential therapeutic applications of the dietary flavonoid didymin. Molecules 2018;23:2547.
7. Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S. Didymin: An orally active citrus flavonoid for targeting neuroblastoma. Oncotarget 2017;8:29428−41.
8. Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 2005;12:930−3.
9. Yamaguchi K, Kumakura S, Murakami T, Someya A, Inada E, Nagaoka I. Ketamine suppresses the substance P-induced productionof IL-6 and IL-8 by human U373MG glioblastoma/ astrocytoma cells. Int J Mol Med 2017;39:687−92.
10. Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res 2014;7:1081−107.
11. Hung JY, Hsu YL, Ko YC, Tsai YM, Yang CJ, Huang MS, et al. Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human nonsmall-cell lung cancer cells in vitro and in vivo. Lung Cancer 2010;68:366−74.
12. Li Q, Miao Z, Wang R, Yang J, Zhang D. Hesperetin ınduces apoptosis in human glioblastoma cells via p38 MAPK activation. Nutr Cancer 2020;72:538−45.
13. Hsu YL, Hsieh CJ, Tsai EM, Hung JY, Chang WA, Hou MF, et al. Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment. Oncol Lett 2016;11:1035−42.
14. Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin N Am 2008;55:97−120.
15. Singhal J, Nagaprashantha LD, Vatsyayan R, Ashutosh, Awasthi S, Singhal SS. Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma. Cancer Prev Res 2012;5:473−83.
16. Shukla K, Sonowal H, Saxena A, Ramana KV. Didymin by suppressing NF-κB activation prevents VEGF-induced angiogenesis in vitro and in vivo. Vascul Pharmacol 2019;115:18−25.
17. Oz EŞ, Aydemir E, Korcum AF, Fiskin K. Thalidomide and irradiation combination therapy increases substance P levels in vitro. Exp Ther Med 2011;2:529.
18. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1998;79:236−43.
19. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K. The neuropeptide substance P activates transcription factor NFkappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997;159:4952−8.
20. Lieb K, Schaller H, Bauer J, Berger M, Schulze-Osthoff K, Fiebich BL. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. J Neurochem 1998;70:1577−83.
21. Kim HI, Lee SJ, Choi YJ, Kim MJ, Kim TY, Ko SG. Quercetin ınduces apoptosis in glioblastoma cells by suppressing Axl/ IL-6/STAT3 signaling pathway. Am J Chin Med 2021;49:767−84.
22. Michaud-Levesque J, Bousquet-Gagnon N, Béliveau R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 2012;318:925−35.
23. Xie C, Kang J, Li Z, Schauss AG, Badger TM, Nagarajan, et al. The açaí flavonoid velutin is a potent anti-inflammatory agent: Blockade of LPS-mediated TNF-α and IL-6 production through inhibiting NF-κB activation and MAPK pathway. J Nutr Biochem 2012;23:1184−91.